Forward-Looking Statements Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including related to the completed IMPACT trial, or the ongoing RECLAIM and RESTORE trials, the timing of key milestones for the Companys clinical programs, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Companys financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
DE-AC02-06CH11357
Why GLP-1 Users Need Electrolytes And Most Don't Know It Jun 9 3 min read If you're taking a GLP-1 medication like Ozempic, Wegovy or Mounjaro, you've probably heard plenty about what to eat, how to manage side effects and what to expect as the weeks go on
In 16 studies with 9,580 participants with pre-existing DR, RAS inhibitors decreased the progression of DR by 13% (p=0.00006)
The bigger issue comes down to the stomach
This intake captures relevant medical history, current medications, biometric indicators, and other factors required for clinical assessment
